Sagimet Biosciences: Making The Bull Case For Differentiated Denifanstat

Sagimet Biosciences receives a Buy rating, driven by denifanstat's potential in MASH and acne, despite higher risk. Denifanstat met all endpoints in Phase 2b MASH and Phase 3 China acne trials, supporting optimism for US acne Phase 3. SGMT's near-term catalysts include US Phase 3 acne trial initiation and milestone payments from China partner Ascletis.